In short
Clinical trials are investigating Ataluren in a rare immune system disorder called LRBA deficiency. These studies look at whether Ataluren can improve symptoms, quality of life, and hospital use in affected patients. The trial data here includes a single-patient Phase 2 study.
Key points
- Clinical trials of Ataluren in the provided data focus on a rare immune disorder called LRBA deficiency. The study is a Phase 2, single-patient trial in one person with severe common variable immunodeficiency and autoimmunity. Researchers looked at whether Ataluren could improve symptoms such as lymphoproliferation, chronic diarrhea, and ascites. They also measured quality of life, weight, diarrhea episodes, and hospitalizations. The trial was completed and included a check of tolerability in the patient.
Trial overview
The provided trial studied Ataluren in one patient with a rare immune disorder linked to LRBA gene mutations. It was an interventional study, which means the patient received a treatment and the research team measured the results.
Condition and patient group
The condition studied was LRBA deficiency due to homozygous nonsense mutations, also described as severe common variable immunodeficiency with autoimmunity. This rare genetic disorder can cause too many lymphocytes, low antibody levels, recurrent infections, and autoimmune problems.
The trial was a single-patient study, so it included only one person. The source also notes that this disease may affect the gut, lungs, and brain, and may raise the risk of lymphoma, which is a type of cancer.
Study design and phase
This was a Phase 2 trial. Phase 2 studies usually look for early signs that a treatment may help, while also checking how well it is tolerated.
The study status was Completed. The intervention listed two forms of Translarna granules for oral suspension, both given orally.
What the trial measured
The main outcome compared the treatment period with a five-year pre-treatment period. Researchers looked for improvement in quality of life, weight, diarrhea episodes, and the number of hospitalizations.
The brief summary also says the study examined clinical efficacy in normalizing lymphoproliferative symptoms, including lymphoproliferation, chronic diarrhea, and ascites. It also assessed clinical tolerability in the single patient.
What the study aimed to learn
The study aimed to see whether Ataluren could help control immune-related symptoms in a patient with LRBA deficiency. It also aimed to learn whether the treatment could improve daily health measures such as weight, diarrhea, and hospital use.
Because this was a single-patient study, the results can help generate ideas for future research, but they do not prove that the treatment will work for everyone with the same condition.